<DOC>
	<DOC>NCT00092807</DOC>
	<brief_summary>This is an extension study for patients having unusually high absorption of non-cholesterol sterols, resulting in heart-related diseases. This study will evaluate the long term safety and the ability to lower cholesterol levels with an investigational drug.</brief_summary>
	<brief_title>Sitosterolemia Extension Study (0653-003)(COMPLETED)</brief_title>
	<detailed_description>The duration of treatment is 52 weeks.</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Metabolism, Inborn Errors</mesh_term>
	<mesh_term>Lipid Metabolism, Inborn Errors</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Patients with elevated sitosterol levels while taking current medication Patient has a condition which, in the opinion of the investigator, might pose a risk to the patient, interfere with participation in the study, or does not meet the additional criteria as required by the study.</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Homozygous Sitosterolemia</keyword>
</DOC>